Goal: improve future decision-making in the selection of drugs to advance to clinical trials in Duchenne muscular dystrophy President and COO Laura with our partners…

Innovative device could power smaller, faster trials for Duchenne muscular dystrophy and open clinical trial participation to broader range of patients   A key focus…

Today, we are grateful and encouraged to announce that three of our partner organizations are throwing their weight — and some serious financial firepower —…

You may remember that in 2017, we teamed up with Duchenne UK and Joining Jack to fund research into the potential of neutrophil elastase inhibitors…

Last week, The New York Times ran this article about Duchenne. The story mentions the incredible breakthroughs that are currently taking place in the field, but it also highlights…

We recently launched one of our biggest and most important initiatives: The Duchenne Program at UMass Medical School. This brand-new clinic provides coordinated, comprehensive care…

A mission-critical need right now in the fight against Duchenne is the development of good tools to help evaluate whether a new treatment is working.…

Several DMD organizations recently teamed up to fund a Phase 2 clinical trial of a new therapy for Duchenne muscular dystrophy (DMD) – Carmeseal-MD. Carmeseal-MD…

Charley's Fund, Duchenne UK, and Joining Jack recently announced a collaborative grant to Dr. Dada Pisconti of the University of Liverpool in England. With this…